Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 5, 2006, Pages 611-619

  Troost, Pieter W ^a   Steenhuis, Mark Peter ^a   Tuynman Qua, Hanneke G ^b   Kalverdijk, Luuk J ^a   Buitelaar, Jan K ^c   Minderaa, Ruud B ^a   Hoekstra, Pieter J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ELI LILLY AND COMPANY   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; MELATONIN; METHYLPHENIDATE; PIPAMPERONE; QUETIAPINE; RISPERIDONE;

ABERRANT BEHAVIOR CHECKLIST; ADOLESCENT; AGGRESSION; AGITATION; ANOREXIA; ANXIETY; ARTICLE; ASPERGER SYNDROME; ATENTION DEFICIT HYPERACTIVITY DISORDER RATING SCALE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER INDEX; AUTISM; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; CONNERS PARENT RATING SCALE; CONSTIPATION; DROWSINESS; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERACTIVITY; IRRITABILITY; MALE; MOOD DISORDER; NAUSEA; OPPOSITIONAL DEFIANT DISORDER; OUTCOME ASSESSMENT; PILOT STUDY; RATING SCALE; RHINITIS; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; TACHYCARDIA; TIC; TITRIMETRY; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; MALE; PERSONALITY ASSESSMENT; PILOT PROJECTS; PROPYLAMINES; TREATMENT OUTCOME;

EID: 33750930909     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.611     Document Type: Article

References (37)

1. Aman MG: Stimulant drugs in the developmental disabilities revisited. J Dev Phys Disab 4:347-366, 1996.
2. Aman MG: Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Semin Pediatr Neurol 11:225-228, 2004.
3. Aman MG, Singh NN, Stewart AW, Field CJ: The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Men Defic 89:485-491, 1985.
4. Aman MG, Kern RA, McGhee DE, Arnold LE: Fenfluramine and methylphenidate in children with mental retardation and attention deficit hyperactivity disorder: Laboratory effects. J Autism Dev Disord 23:491-506, 1993.
5. Aman MG, Van Bourgondien ME, Wolford PL, Sarphare G: Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 34:1672-1681, 1995.
6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR). Washington (DC), American Psychiatric Association, 2000.
7. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227-239, 1989.
8. Biederman J, Spencer T: Non-stimulant treatments for ADHD. Eur Child Adolesc Psychiatry 9(Suppl 1):I51-I59, 2000.
9. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS: A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777-784, 1989.
10. Biederman J, Spencer T: Depressive disorders in childhood and adolescence: A clinical perspective. J Child Adolesc Psychopharmacol 9:233-237, 1999.
11. Buitelaar JK, Willemsen-Swinkels SH: Medication treatment in subjects with autistic spectrum disorders. Eur Child Adolesc Psychiatry 9(Suppl 1):I85-I97, 2000.
12. Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Pagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D: A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 13:249-257, 2004.
13. Cohen J: Statistical power analysis for the behavior sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
14. Conners CK: Conners' Rating Scales-Revised, Technical Manual. Toronto: Multi-Health Systems Inc., 1997.
15. Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, Weller RA, Khayrallah M, Ascher J: Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314-1321, 1996.
16. DuPaul G, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. The Guildford Press, 1998
17. Gillberg C, Lothgren M, Fitzgerald P, Cottrell S, Burridge J, Aristides M. Atomoxetine versus methylphenidate as a treatment for ADHD in children and adolescents: A meta-analysis of safety data incorporating active comparator and placebo controlled trials. Paris, European Society for Child and Adolescent Psychiatry (ECAP) Annual Meeting, 2003 (abstract).
18. Handen BL, Johnson CR, Lubetsky M: Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245-255, 2000.
19. Jaselskis CA, Cook EH, Jr., Fletcher KE, Leventhal BL: Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322-327, 1992.
20. Jou RJ, Handen BL, Hardan AY: Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15:325-330, 2005.
21. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biedermari J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D: Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41: 776-784, 2002.
22. Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659-685, 1994.
23. Michelson D, Paries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108:E83, 2001.
24. Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang S, Biederman J: Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43:896-904, 2004.
25. Pliszka SR, McCracken JT, Maas JW: Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 35:264-272, 1996.
26. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ: Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14:233-241, 2004.
27. Prince JB, Wilens TE, Biederman J, Spencer TJ, Millstein R, Polisner DA, Bostic JQ: A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10:193-204, 2000.
28. RUPP, Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism for serious behavioral problems. N Engl J Med 347:314-321, 2002.
29. RUPP, Research Units on Pediatric Psychopharmacology Autism Network: Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266-1274, 2005.
30. Rutter M, Le Couteur A, Lord C: Autism Diagnostic Interview Revised. Manual. Los Angeles: Western Psychological Services, 2003.
31. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leekman JF: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067-1074, 2001.
32. Spencer T, Biederman J, Wilens TE, Faraone SV: Adults with attention-deficit/hyperactivity disorder: A controversial diagnosis. J Clin Psychiatry 59(Suppl 7):59-68, 1998.
33. Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK, Tarazi R, Faraone SV: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 59:649-656, 2002.
34. Troost PW, Lahuis BE, Steenhuis MP, Ketelaars CEJ, Buitelaar J, England K, Scahill L, Minderaa R, Hoekstra PJ: Long term effects of Risperidone in children with Autism Spectrum Disorders: A placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44:1137-1144, 2005.
35. Tse WS, Bond AJ: Difference in serotonergic and noradrenergic regulation of human social behaviours. Psychopharmacology (Berl) 159:216-221, 2002.
36. Volkmar FR, Lord C, Bailey A, Schultz RT, Klin A: Autism and pervasive developmental disorders. J Child Psychol Psychiatry 45:135-170, 2004.
37. Wechsler D: Wechsler Intelligence Scale for Children. San Antonio (Texas), The Psychological Corporation, 1991.